Literature DB >> 28296025

Renal denervation beyond the bifurcation: The effect of distal ablation placement on safety and blood pressure.

Martine M A Beeftink1, Wilko Spiering2, Mark R De Jong3, Pieter A Doevendans1, Peter J Blankestijn4, Arif Elvan3, Jan-Evert Heeg5, Michiel L Bots6, Michiel Voskuil1.   

Abstract

Renal denervation may be more effective if performed distal in the renal artery because of smaller distances between the lumen and perivascular nerves. The authors reviewed the angiographic results of 97 patients and compared blood pressure reduction in relation to the location of the denervation. No significant differences in blood pressure reduction or complications were found between patient groups divided according to their spatial distribution of the ablations (proximal to the bifurcation in both arteries, distal to the bifurcation in one artery and distal in the other artery, or distal to the bifurcation in both arteries), but systolic ambulatory blood pressure reduction was significantly related to the number of distal ablations. No differences in adverse events were observed. In conclusion, we found no reason to believe that renal denervation distal to the bifurcation poses additional risks over the currently advised approach of proximal denervation, but improved efficacy remains to be conclusively established. ©2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  hypertension-general; optimized treatment; renal denervation

Mesh:

Year:  2017        PMID: 28296025      PMCID: PMC8030832          DOI: 10.1111/jch.12989

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  31 in total

1.  Renal artery nerve distribution and density in the porcine model: biologic implications for the development of radiofrequency ablation therapies.

Authors:  Armando Tellez; Serge Rousselle; Taylor Palmieri; William R Rate; Joan Wicks; Ashley Degrange; Chelsea M Hyon; Carlos A Gongora; Randy Hart; Will Grundy; Greg L Kaluza; Juan F Granada
Journal:  Transl Res       Date:  2013-07-30       Impact factor: 7.012

2.  Post mortem study of the depth and circumferential location of sympathetic nerves in human renal arteries--implications for renal denervation catheter design.

Authors:  Andrew K Roy; Aurelie Fabre; Melanie Cunningham; Una Buckley; Thomas Crotty; David Keane
Journal:  Catheter Cardiovasc Interv       Date:  2015-05-27       Impact factor: 2.692

3.  Renal denervation for the treatment of hypertension: the Dutch consensus.

Authors:  W L Verloop; W R P Agema; C P Allaart; P J Blankestijn; M Khan; M Meuwissen; W M Muijs van de Moer; B J W M Rensing; W Spiering; M Voskuil; P A Doevendans
Journal:  Neth J Med       Date:  2014-11       Impact factor: 1.422

4.  Blood pressure response to renal nerve stimulation in patients undergoing renal denervation: a feasibility study.

Authors:  P Gal; M R de Jong; J J J Smit; A Adiyaman; J A Staessen; A Elvan
Journal:  J Hum Hypertens       Date:  2014-10-23       Impact factor: 3.012

5.  Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.

Authors:  Michel Azizi; Marc Sapoval; Philippe Gosse; Matthieu Monge; Guillaume Bobrie; Pascal Delsart; Marco Midulla; Claire Mounier-Véhier; Pierre-Yves Courand; Pierre Lantelme; Thierry Denolle; Caroline Dourmap-Collas; Hervé Trillaud; Helena Pereira; Pierre-François Plouin; Gilles Chatellier
Journal:  Lancet       Date:  2015-01-26       Impact factor: 79.321

Review 6.  Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.

Authors:  Alexandre Persu; Sverre Kjeldsen; Jan A Staessen; Michel Azizi
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

7.  2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension.

Authors: 
Journal:  J Hypertens       Date:  2013-10       Impact factor: 4.844

8.  Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study.

Authors:  Eva E Vink; Roel Goldschmeding; Aryan Vink; Callista Weggemans; Ronald L A W Bleijs; Peter J Blankestijn
Journal:  Nephrol Dial Transplant       Date:  2014-05-29       Impact factor: 5.992

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Renal denervation beyond the bifurcation: The effect of distal ablation placement on safety and blood pressure.

Authors:  Martine M A Beeftink; Wilko Spiering; Mark R De Jong; Pieter A Doevendans; Peter J Blankestijn; Arif Elvan; Jan-Evert Heeg; Michiel L Bots; Michiel Voskuil
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-03-14       Impact factor: 3.738

View more
  3 in total

1.  Finding the best ablation strategy for renal denervation: A continuing saga.

Authors:  Kyriakos Dimitriadis; Costas Tsioufis; Dimitrios Tousoulis
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-03-21       Impact factor: 3.738

2.  Renal denervation beyond the bifurcation: The effect of distal ablation placement on safety and blood pressure.

Authors:  Martine M A Beeftink; Wilko Spiering; Mark R De Jong; Pieter A Doevendans; Peter J Blankestijn; Arif Elvan; Jan-Evert Heeg; Michiel L Bots; Michiel Voskuil
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-03-14       Impact factor: 3.738

3.  Safety of catheter-based radiofrequency renal denervation on branch renal arteries in a porcine model.

Authors:  Atsushi Sakaoka; Serge D Rousselle; Hitomi Hagiwara; Armando Tellez; Brad Hubbard; Kenichi Sakakura
Journal:  Catheter Cardiovasc Interv       Date:  2018-11-08       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.